169222-42-8

Basic information

• Product Name: 4-(Trifluoromethoxy)phenylmagnesium bromide
• Synonyms: 4-(Trifluoromethoxy)phenylmagnesium bromide;4-(Trifluoromethoxy)phenylmagnesium bromide solution ;4-(Trifluoromethoxy)phenylmagnesium bromide solution 0.5 M in THF;(4-(Trifluoromethoxy)phenyl)magnesium bromide, 0.50 M in THF;(4-(Trifluoromethoxy)phenyl)magnesium bromide, 0.50 M in 2-MeTHF
• CAS NO: 169222-42-8
• Molecular Formula: C₇H₄BrF₃MgO
• Molecular Weight: 265.3102696
• Product Categories: Aryl;Grignard Reagents;Organometallic Reagents;Grignard Reagent
• Mol File: 169222-42-8.mol
• Article Data: 4

Chemical Properties

• Flash Point: -30 °C
• Appearance: /
• Density: 0.975 g/mL at 25 °C
• CAS DataBase Reference: 4-(Trifluoromethoxy)phenylmagnesium bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Trifluoromethoxy)phenylmagnesium bromide(169222-42-8)
• EPA Substance Registry System: 4-(Trifluoromethoxy)phenylmagnesium bromide(169222-42-8)

Safety Data

• Hazard Codes: F,C
• Statements: 11-14-19-34-40-37
• Safety Statements: 16-26-36/37/39-45
• RIDADR: UN 2924 3/PG 2
• WGK Germany: 3
• Hazardous Substances Data: 169222-42-8(Hazardous Substances Data)

Usage

Uses

Reactant for:Preparation of chromanol derivatives as novel class of CETP inhibitors for treatment of cardiovascular diseasePd-catalyzed cross couplingPreparation of indazole-pyridine derivatives as protein kinase B/Akt inhibitors with reduced hypotension, via Stille coupling, Mitsunobu reaction and copper-catalyzed aziridine ring-opening reaction

Upstream product

• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 7439-95-4 magnesium 
• 456-55-3 1-trifluoromethoxybenzene 

Downstream Products

• 1346239-96-0 (5-bromo-2-chloro-phenyl)-[4-(trifluoromethoxy)phenyl]methanone 
• 1181681-61-7 (5-bromo-2-chloro-phenyl)-[4-(trifluoromethoxy)phenyl]methanol 
• 1181681-65-1 4-bromo-1-chloro-2-[[4-(trifluoromethoxy)phenyl]methyl]benzene 
• 1358580-81-0 (2S,3R,4S,5S,6R)-2-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)-2-methoxy-tetrahydropyran-3,4,5-triol 
• 1358580-84-3 (2S,3R,4S,5S,6R)-6-[(tert-butyl(dimethyl)silyl)oxymethyl]-2-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-2-methoxy-tetrahydropyran-3,4,5-triol 
• 1358580-87-6 [[(2R,3R,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-methoxy-tetrahydropyran-2-yl]methoxy]tert-butyl-dimethyl-silane 
• 1358580-89-8 [(2R,3R,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-methoxy-tetrahydropyran-2-yl]methanol 
• 1358580-91-2 (2S,3S,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-methoxy-tetrahydropyran-2-carbaldehyde 
• 1358580-93-4 (2S,3S,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-2-carbaldehyde 
• 1358580-96-7 [(3S,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-2-yl]methanol 
• 1358580-97-8 [(1S,2S,3S,4R,5S)-2,3,4-tribenzyloxy-5-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6,8-dioxabicyclo[3.2.1]octan-1-yl]methanol 
• 1358579-30-2 (1S,2S,3S,4R,5S)-5-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo-[3.2.1]octane-2,3,4-triol 
• 1426520-69-5 (4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}phenyl)methanamine 
• 180160-91-2 4-(4-(trifluoromethoxy)phenyl)piperidine 

Relevant articles and documents

Cobalt-Catalyzed Electrophilic Amination of Aryl- and Heteroarylzinc Pivalates with N-Hydroxylamine Benzoates

Aryl- and heteroarylzinc pivalates can be aminated with O-benzoylhydroxylamines at 25 °C within 2–4 h in the presence of 2.5–5.0 % CoCl2?2 LiCl to furnish the corresponding tertiary arylated or heteroarylated amines in good yields. This electrophilic amination also provides access to diarylamines and aryl(heteroaryl)amines. A new tuberculosis drug candidate (Q203) was prepared in six steps and 56 % overall yield by using this cobalt-catalyzed amination as the key step.

C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed.